Oxford Biomedica/£OXB
07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX
About Oxford Biomedica
Ticker
£OXB
Sector
Primary listing
LSE
Employees
900
Headquarters
Website
Oxford Biomedica Metrics
BasicAdvanced
£732M
-
-£0.36
0.95
-
Price and volume
Market cap
£732M
Beta
0.95
52-week high
£6.60
52-week low
£3.48
Average daily volume
292K
Financial strength
Current ratio
1.891
Quick ratio
1.592
Long term debt to equity
307.993
Total debt to equity
322.112
Interest coverage (TTM)
-2.28%
Profitability
EBITDA (TTM)
-12.566
Gross margin (TTM)
44.12%
Net profit margin (TTM)
-24.51%
Operating margin (TTM)
-18.15%
Effective tax rate (TTM)
-4.07%
Revenue per employee (TTM)
£170,000
Management effectiveness
Return on assets (TTM)
-7.44%
Return on equity (TTM)
-75.20%
Valuation
Price to revenue (TTM)
4.183
Price to book
19.75
Price to tangible book (TTM)
76.85
Price to free cash flow (TTM)
-52.588
Free cash flow yield (TTM)
-1.90%
Free cash flow per share (TTM)
-0.116
Growth
Revenue change (TTM)
55.44%
Earnings per share change (TTM)
-74.65%
3-year revenue growth (CAGR)
6.39%
10-year revenue growth (CAGR)
27.54%
3-year earnings per share growth (CAGR)
8.95%
10-year earnings per share growth (CAGR)
6.20%
What the Analysts think about Oxford Biomedica
Analyst ratings (Buy, Hold, Sell) for Oxford Biomedica stock.
Bulls say / Bears say
Oxford Biomedica posted 44% full-year 2024 revenue growth to £128.8 million (organic growth 81%) and recorded an operating EBITDA profit of £5.0 million in H2 2024, marking a pivot to mid-year profitability. (LSE RNS)
In H1 2025, the company generated revenues of £73.2 million (up 44% year-on-year), secured £149 million in contracted client orders, expanded its revenue backlog to £222 million, and narrowed its operating EBITDA loss to £8.3 million. (Sharecast)
After H1, Oxford Biomedica strengthened its balance sheet by securing a four-year loan facility of up to $125 million and raising around £60 million via a share placing, supporting expansion of its global manufacturing, particularly in the U.S. (GuruFocus)
Despite strong revenue momentum, Oxford Biomedica expects only a low single-digit million pounds of operating EBITDA profit for the full year 2025, highlighting limited near-term earnings upside. (Sharecast)
Although sales are rising, the group posted an operating EBITDA loss of £15.3 million for full-year 2024, underscoring ongoing profitability challenges. (LSE RNS)
Oxford Biomedica had an operating cash outflow of £4.8 million in H1 2025, indicating continuing cash burn and funding needs even as revenue improves. (GuruFocus)
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.
Oxford Biomedica Financial Performance
Revenues and expenses
Oxford Biomedica Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Oxford Biomedica stock?
Oxford Biomedica (OXB) has a market cap of £732M as of October 27, 2025.
What is the P/E ratio for Oxford Biomedica stock?
The price to earnings (P/E) ratio for Oxford Biomedica (OXB) stock is 0 as of October 27, 2025.
Does Oxford Biomedica stock pay dividends?
No, Oxford Biomedica (OXB) stock does not pay dividends to its shareholders as of October 27, 2025.
When is the next Oxford Biomedica dividend payment date?
Oxford Biomedica (OXB) stock does not pay dividends to its shareholders.
What is the beta indicator for Oxford Biomedica?
Oxford Biomedica (OXB) has a beta rating of 0.95. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.